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Summary
Background.— Radiofrequency ablation is an effective treatment for typical atrial ﬂutter (AFL)
but long-term results may be hampered by atrial ﬁbrillation (AF).
Aims.— To determine the incidence and predictors of AF during very long-term follow-up after
radiofrequency ablation of typical AFL.
Methods.— From November 1998 to December 2000, patients who underwent successful
radiofrequency ablation for cavotricuspid isthmus-dependent AFL in our centre were followed
prospectively.
Results.— Of the 135 patients followed (mean age: 62± 11 years), 69 (51%) had structural heart
disease. Mean left ventricular ejection fraction was 52± 11%. Patients were analysed according
Abbreviations: AAD, antiarrhythmic drug; AF, atrial ﬁbrillation; AFL, atrial ﬂutter; ECG, electrocardiogram; IQR, interquartile range;
LA, left atrial/atrium; RF, radiofrequency.
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Conclusion.— À long terme, la plupart des patients bénéﬁciant de l’ablation d’un ﬂutter atrial
typique présentent de la FA. L’antécédent de FA avant l’ablation et la dilatation de l’oreillette
gauche prédisent la survenue de FA après l’ablation.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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Packground
he incidence of AFL in the general population is
8/100,000 person-years [1]. Some risk factors for develop-
ng this condition, such as age, heart failure and chronic
bstructive pulmonary disease, also predispose to AF. The
wo arrhythmias share common pathophysiological features
2—4] and often coexist. For instance, Halligan et al.
eported that 56% of patients with lone AFL develop AF
n average of 5± 6 years after the diagnosis of AFL [5].
adiofrequency (RF) ablation of the cavotricuspid isthmus
s now an established, safe and effective treatment for
ypical AFL with more than 90% success when complete bidi-
ectional isthmus block is the sought procedural end-point
6—21]. However, the long-term result may be hampered by
ostablation AF, whether episodes of AF have been docu-
ented before the procedure or not. Although 17—22% of
S
O
watients experience a ﬁrst episode of AF during the ﬁrst 6
onths after the procedure [9,12], the cumulative prob-
bility of developing postablation AF increases over time.
llis et al. reported recently that 82% of patients with lone
FL developed drug-refractory AF after a mean follow-up of
9± 11months [14]. All series published to date have a mean
ollow-up of less than 4 years. The purpose of this study was
o determine the incidence and predictors of AF during very
ong-term follow-up after RF ablation of typical AFL.
atients and methodsG. Moubarak et al.
to preablation AF history: group 1 included patients with AFL (N = 71); group 2 included patients
with AFL and AF (N = 64). During a median [interquartile range] follow-up of 7.8 [7.0—8.4] years,
new-onset or recurrent AF was experienced by 99 (73%) patients: 44 (62%) in group 1 and 55 (86%)
in group 2. Although most episodes occurred in the ﬁrst 2 years postablation, AF prevalence
increased continuously over time. Preablation AF history predicted AF occurrence (hazard ratio:
2.10, 95% conﬁdence interval: 1.40—3.14; p = 0.001), as did left atrial diameter (hazard ratio:
1.05 per 1mm increase; 95% conﬁdence interval: 1.02—1.08; p < 0.001). AF evolved to become
permanent in 24% of group 1 and 47% of group 2 patients (p = 0.005).
Conclusion.— During long-term follow-up, most patients will experience AF after ablation of
typical AFL. Preablation AF history and left atrial enlargement predict postablation AF occur-
rence.
© 2009 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— L’ablation par radiofréquence (RF) est un traitement efﬁcace du ﬂutter atrial typ-
ique mais la survenue de ﬁbrillation atriale (FA) pourrait réduire le bénéﬁce de la procédure à
long terme.
Objectifs.— Le but de cette étude était de déterminer l’incidence et les facteurs prédictifs de
FA lors du suivi à très long terme après ablation par RF de ﬂutter atrial typique.
Méthodes.— Les patients ayant bénéﬁcié de l’ablation par RF de ﬂutter atrial droit isthme-
dépendant dans notre centre de novembre 1998 à décembre 2000 ont été suivis de manière
prospective.
Résultats.— La population comprenait 135 patients (âge moyen : 62± 11 ans) dont 69 (51 %)
avaient une cardiopathie sous-jacente. La fraction d’éjection ventriculaire gauche était de
52± 11%. Les patients ont été analysés en fonction de la présence éventuelle d’un antécédent
de FA : le groupe 1 incluait des patients avec uniquement un ﬂutter (n = 71) et le groupe 2 des
patients avec à la fois du ﬂutter et de la FA (n = 64). Au cours d’une durée médiane [intervalle
interquartile] de suivi de 7.8 [7.0—8.4] ans, 99 patients (73 %) ont présenté un épisode de FA:
44 (62 %) dans le groupe 1 et 55 (86 %) dans le groupe 2. Même si la plupart des épisodes sont
survenus au cours des deux premières années suivant l’ablation, la prévalence de la FA n’a
cessé d’augmenter par la suite. L’antécédent de FA avant l’ablation prédisait la survenue de FA
après l’ablation (hazard ratio : 2,10 ; intervalle de conﬁance à 95% : 1,40—3,14 ; p = 0,001), de
même que le diamètre de l’oreillette gauche (hazard ratio : 1,05 par augmentation de 1mm;
intervalle de conﬁance à 95% : 1,02—1,08 ; p < 0,001). La FA a évolué vers une forme permanente
chez 24% des patients du groupe 1 et 47 % des patients du groupe 2 (p = 0,005).tudy population
ne hundred and thirty-nine consecutive patients under-
ent cavotricuspid isthmus ablation for typical AFL at our
w
o
r
t
w
d
p
w
t
S
S
s
a
I
p
a
S
u
c
t
A
w
y
s
t
a
R
S
O
p
c
T
w
(
t
a
r
5
o
ﬁ
b
a
c
i
b
(
n
t
aAtrial ﬁbrillation after atrial ﬂutter ablation
tertiary care university hospital between November 1998
and December 2000. Cavotricuspid isthmus-dependence of
AFL was diagnosed by the presence of a characteristic pat-
tern on the surface ECG (negative sawtooth waves in inferior
leads and usually positive waves in lead V1) and/or entrain-
ment mapping during electrophysiological study. Immediate
success of anatomically-guided linear ablation between the
tricuspid annulus and the inferior vena cava was deﬁned
by complete bidirectional isthmus conduction block [22,23]
persisting at least 30min after the last RF energy appli-
cation. Patients in whom the ablation was successful were
eligible for prospective follow-up. The study patients were
divided into two groups according to their arrhythmic his-
tory. Group 1 comprised patients with lone AFL (deﬁned
as AFL with no documented AF before ablation) and group
2 comprised patients with AFL and at least one docu-
mented episode of AF before ablation. Thus group 2 included
patients in whom the clinically predominant arrhythmia was
AFL (more episodes of AFL than AF, or same number with no
more than two episodes of AF), patients in whom the clini-
cally predominant arrhythmia was AF (more episodes of AF
than AFL, or same number but at least three episodes of AF)
and patients who developed AFL while receiving class IC or
III AADs for AF.
All patients underwent transthoracic echocardiography
before the ablation procedure for assessment of left ven-
tricular function, cardiac chamber sizes and the presence of
signiﬁcant valvular heart disease. Left ventricular hypertro-
phy was deﬁned by wall thickness of at least 13mm. The left
atrium (LA) was considered to be enlarged when its diameter
in parasternal long-axis view was above 45mm. Structural
heart disease was deﬁned by the presence of at least one
of the following: left ventricular ejection fraction below
50%, left ventricular hypertrophy, signiﬁcant valvulopathy,
history of coronary artery disease or congenital heart dis-
ease.
Before ablation, all patients were treated with oral anti-
coagulants aiming at a therapeutic international normalized
ratio of 2 to 3 for at least 3 weeks. AADs were not dis-
continued before ablation. Study protocol was approved by
the local ethics committee and all patients gave informed
consent.
Follow-up
Oral anticoagulation was pursued for at least 1month.
Thereafter, the need for anticoagulation was assessed
according to the presence of risk factors for thromboem-
bolism [24]. Whenever possible, AADs were stopped after
the procedure in patients with lone AFL. AADs were contin-
ued in patients with a history of preablation AF, if frequent or
poorly-tolerated episodes of AF were documented recently
before the ablation procedure. Subsequently, AAD prescrip-
tion was left to the individual physician’s discretion. Patients
were scheduled for clinic visits at our institution at 1 month,
and at 3, 6 and 12 months, with a 12-lead ECG record-
ing. Thereafter, yearly evaluations were conducted either
at our institution or at the referring cardiologist’s practice.
In the latter case, the cardiologist was reminded each year
to monitor patient status. A 24-hour Holter recording was
obtained when patients complained of symptoms suggestive
of arrhythmias.
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After a blanking period of 1 month, documented AF
as considered to be signiﬁcant if it was symptomatic
r it was asymptomatic and discovered on a routine ECG
ecording (for 24-hour Holter ECG or pacemaker memory,
otal AF duration had to exceed 30min). Hospital records
ere veriﬁed regularly to monitor hospitalizations in any
epartment at our institution. At the end of the study, all
atients’ arrhythmic status and current drug prescriptions
ere obtained by contacting the patients or their rela-
ives.
tatistical analysis
tatistical analysis was performed with SAS software ver-
ion 9.1 (SAS Institute, Cary, NC, USA). Continuous variables
re reported as mean± standard deviation or median and
QR, and categorical variables are reported as number of
atients in each category and corresponding percentage,
s appropriate. Comparison of groups was performed with
tudent’s t-test or the Wilcoxon’s rank sum test for contin-
ous variables and the Chi-square or Fischer’s exact test for
ategorical variables, as appropriate. To identify risk fac-
ors associated independently with time to occurrence of
F, variables found to be signiﬁcant in a univariate analysis
ere entered into a stepwise Cox model. Kaplan-Meier anal-
sis was performed to determine the probability of AF-free
urvival. Survival curves were compared using the log-rank
est. All values were considered to be statistically signiﬁcant
t p less than 0.05.
esults
tudy population
f the 139 patients undergoing RF ablation, immediate
rocedural success was achieved in 135 (97%). Baseline
haracteristics of the study population are summarized in
able 1. There were 122 men and 13 women. Mean age
as 62± 11 years. Structural heart disease was present in 69
51%) patients, hypertension in 56 (41%) and mitral regurgi-
ation in 18 (13%). Mean left ventricular ejection fraction
nd left atrial (LA) diameter were 52± 11% and 42± 7mm,
espectively. Left ventricular ejection fraction was below
0% in 41 (30%) patients. Eleven patients (8%) had a history
f ischaemic stroke or transient ischaemic attack. AFL was
rst documented at a median IQR time of 11 [3—48] months
efore the ablation procedure and patients had experienced
mean of 2.9± 1.7 episodes of AFL at the time of the pro-
edure.
There were 71 (53%) patients in group 1 and 64 (47%)
n group 2. Other than the fact that group 2 patients had
een treated with more AAD regimens than group 1 patients
2.3± 1.2 and 1.4± 1.1, respectively; p < 0.001), there were
o baseline differences between the two groups. In group 2,
he clinically predominant arrhythmia was AFL in 28 patients
nd AF in 20 patients. The remaining 16 patients devel-
ped AFL while receiving class IC or III AADs for AF. AF was
rst documented at a median IQR time of 30 [4—91] months
efore the procedure and a mean of 2.1± 1.2 episodes of
F had been recorded. Forty-ﬁve of these patients had an
pisode of AF in the year preceding the ablation.
528 G. Moubarak et al.
Table 1 Baseline characteristics of the study population.
All patients (N = 135) Group 1 (N = 71) Group 2 (N = 64) pa
Age (years)b 62± 11 62± 12 62± 10 0.67
Men/women (N/N) 122/13 65/6 57/7 0.63
Structural heart disease (N [%]) 69 (51) 38 (54) 31 (48) 0.56
Coronary artery disease (N [%]) 13 (10) 10 (14) 3 (5) 0.07
Hypertension (N [%]) 56 (4) 28 (39) 28 (44) 0.61
Diabetes mellitus (N [%]) 15 (11) 8 (11) 7 (11) 0.95
Chronic obstructive pulmonary disease (N [%]) 13 (10) 7 (10) 6 (9) 0.92
Number of failed AAD regimensb 1.8± 1.2 1.4± 1.1 2.3± 1.2 < 0.001
LA diameter, mmb 42± 7 42± 7 43± 7 0.35
Left ventricular ejection fraction (%b) 52± 11 53± 12 52± 10 0.31
Mitral regurgitation of grade≥ 2 (N [%]) 18 (13) 12 (17) 6 (9) 0.20
Time since ﬁrst documentation of AFL (monthsc) 11 [3—48] 11 [3—55] 12 [3—40] 0.53
Number of AFL episodesb 2.9± 1.7 3.0± 1.8 2.9± 1.5 0.87
AAD: antiarrhythmic drug; LA: left atrial; AFL: atrial ﬂutter.
a Group 1 versus group 2.
b Mean± standard deviation.
c Median interquartile range.
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ratio: 2.10, 95% conﬁdence interval: 1.40—3.14; p = 0.001),ollow-up
ADs were maintained at discharge in 39 (29%) patients,
ore frequently in group 2 patients than in group 1 patients
48% versus 11%, respectively; p < 0.001). The median IQR
ollow-up was 7.8 [7.0—8.4] years and was similar in the two
roups. Twenty-eight patients (21%) died at a median IQR of
.9 [3.3—6.1] years after the RF ablation. Thirteen of these
eaths were either sudden or distinctly attributable to a car-
iovascular cause. Recurrences of AFL were documented in
1 (8%) patients, at a median IQR of 5.8 [3.1—8.9] months
fter the procedure. Six (55%) of these recurrences occurred
ithin 6 months after the ablation and nine (82%) occurred
ithin 1 year. All were typical AFLs, due to recovery of isth-
us conduction, and were treated successfully with another
F ablation procedure, with no subsequent relapses. Of the
07 patients who were still alive at the end of follow-up
n February 2008, 73 (68%) were treated with vitamin K
ntagonists, 17 (16%) with aspirin and 37 (35%) with AADs
amiodarone [N = 15], ﬂecainide [N = 14], sotalol [N = 6], and
ibenzoline [N = 2]).
ccurrence of AF after ﬂutter ablation
pontaneous AF occurred in 99 (73%) patients, at a median
QR of 11.4 [2.1—35.7] months after ﬂutter ablation. AF inci-
ence was 62% in group 1 and 86% in group 2 (p = 0.002).
he ﬁrst episode was documented earlier after the abla-
ion procedure in group 2 than in group 1 (median IQR:
.5 [1.4—28.0] months and 15.6 [7.0—55.7] months, respec-
ively, p = 0.011). Nearly half of those ﬁrst episodes of AF
ccurred in the ﬁrst year after the ablation (in 51 patients)
nd two thirds occurred in the ﬁrst 2 years (in 66 patients).
oreover, although 49% of all study patients had experi-
nced AF within 2 years, the prevalence of AF continued to
ncrease over time. After the ﬁrst 2 years, the annual inci-
ence of AF was 6.5% per year. The same trend was observed
a
c
K
t
dn the two groups prespeciﬁed according to preablation his-
ory of AF. In particular, 19 patients (27%) in group 1 (lone
FL) experienced AF within 1 year of ablation and 27 (38%)
ithin 2 years. The AF incidence rate then averaged 3.3%
er year over the remainder of follow-up in this group. A
aplan-Meier analysis estimating survival free of AF accord-
ng to the presence or absence of preablation AF is shown
n Fig. 1.
The initial pattern of presentation of AF was paroxysmal
n 77 (78%) patients, persistent in 12 (12%) and permanent
n 10 (10%). Ultimately, AF evolved to a permanent form in
7 (35%) patients, at a median IQR of 4.2 [1.6—5.3] years
fter the ablation procedure. Permanent AF was encoun-
ered more frequently in group 2 than in group 1 (47% versus
4%, respectively; p = 0.005).
redictors of postablation AF
nivariate analysis showed that patients who experienced
ostablation AF were more likely to have a history of pre-
blation AF, more episodes of preablation AF and more
pisodes of AF occurring in the year preceding the RF
blation procedure than patients who did not experi-
nce postablation AF (Table 2). They also had a larger
A diameter. Age, left ventricular ejection fraction, pres-
nce of structural heart disease, hypertension or mitral
egurgitation was not associated with an increased risk of
ostablation AF. Multivariable analysis showed that two fac-
ors were associated signiﬁcantly with time to occurrence
f AF after RF ablation: history of preablation AF (hazardnd LA diameter (hazard ratio: 1.05 per 1mm increase, 95%
onﬁdence interval: 1.02—1.08; p < 0.001). Fig. 2 shows the
aplan-Meier analysis of survival free of AF according to
he presence or absence of LA enlargement (deﬁned as LA
iameter above 45mm).
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Figure 1. Probability of survival free from atrial ﬁbrillation (AF) as a function of history of preablation AF. Patients with a history of
preablation AF (group 2) have a higher risk of developing postablation AF than patients with lone atrial ﬂutter (group 1) (log-rank: p = 0.0002).
Table 2 Predictors of postablation atrial ﬁbrillation: univariate analysis.
No postablation AF (N = 36) Postablation AF (N = 99) p
Age (yearsa) 61± 13 62± 10 0.97
Men/women (N/N) 30/6 92/7 0.11
Structural heart disease (N [%]) 22 (61) 47 (47) 0.16
Coronary artery disease (N [%]) 6 (17) 7 (7) 0.11
Hypertension (N [%]) 14 (39) 42 (42) 0.71
Diabetes mellitus (N [%]) 3 (8) 12 (12) 0.76
Chronic obstructive pulmonary disease (N [%]) 4 (11) 9 (9) 0.75
Failed AAD regimensa 1.5± 1.2 1.9± 1.2 0.06
LA diameter (mma) 39± 8 43± 7 0.004
Left ventricular ejection fraction (%a) 52± 13 53± 10 0.92
Mitral regurgitation of grade≥ 2 (N [%]) 5 (14) 13 (13) 1.00
P-wave duration (msa) 123± 19 124± 19 0.82
Time since ﬁrst documentation of AFL (monthsb) 12 [2—52] 11 [3—46] 0.82
Number of AFL episodesa 3.0± 2.0 2.9± 1.6 0.83
History of preablation AF (N [%]) 9 (25) 55 (56) 0.002
Number of episodes of AFa 0.4± 0.9 1.2± 1.4 0.002
Episodes of AF occurring in the past year (N [%]) 7 (19) 38 (38) 0.04
AAD: antiarrhythmic drug; LA: left atrial; AF: atrial ﬁbrillation; AFL: atrial ﬂutter.
a Mean± standard deviation.
b Median interquartile range.
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iameter above 45mm have a higher risk of developing postablatio
iscussion
o the best of our knowledge, the follow-up after RF abla-
ion of typical AFL in this prospective study is the longest
o be reported in literature. While only 8% of patients expe-
ienced AFL recurrence, AF occurred in 73% of them during
median follow-up of 7.8 years. The ﬁrst AF episode was
ocumented in the ﬁrst year after the RF ablation in approx-
mately half of the patients. A majority (62%) of patients
ithout previously documented AF developed postablation
F. Nevertheless, history of preablation AF is an important
redictor of postablation AF, as is LA enlargement.
ecurrence of AFL
arlier studies of RF ablation of the cavotricuspid isth-
us for typical AFL yielded unsatisfactory results, with an
mmediate procedural success rate as low as 78% and a
ecurrence rate as high as 42% during short follow-up [25].
ince complete bidirectional isthmus block was advocated
s a procedural end-point, the rate of success has risen
o more than 90% [6,7,9,10,12,13,16—18,20]. As in other
eports, most recurrences in our study were discovered early
a
c
i
[function of left atrial (LA) diameter. Patients with an enlarged LA
than patients with a normal LA diameter (log-rank: p = 0.0048).
fter the procedure and were due to recovery of isthmus
onduction. Incomplete isthmus block has been described as
predictor for AFL recurrence [16] but such patients were
ot included in our study.
nterrelationship between AFL and AF
he two arrhythmias share common pathophysiological fea-
ures. As in AF, electrical remodelling in both paroxysmal and
hronic AFL is characterized by a spatially heterogeneous
ecrease in action potential duration and conduction veloc-
ty, contributing to a lengthening of the activation wavefront
2—4]. Thus, there is a continuum spanning from the sin-
le stable wavefront of AFL to the multiple nonstationary
avebreaks of AF, which is in part underlain by progressive
hortening of action potential duration [26]. Another mech-
nism by which AFL leads to AF is when the AFL circuit has
very short cycle length, driving the atria so fast that some
reas cannot follow in a 1:1 fashion, resulting in ﬁbrillatory
onduction [27,28].
Conversely, Waldo and Feld suggested that in most
nstances there cannot be AFL without preexisting AF
29]. Initiation and perpetuation of typical AFL, a
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macro-reentrant circuit between natural endocardial bar-
riers in the right atrium, depend on the existence of a line
of block between the vena cavae in the region of the crista
terminalis. In most patients, there is no physiological line
of block and it is during transitional preceding AF that a
functional line develops [30,31].
In clinical practice, this close interplay between the two
arrhythmias also translates into a high incidence of AF fol-
lowing RF ablation of typical AFL, ranging from 17—58% after
a follow-up of 6—36months [6—10,12,13,15—17,19,20]. Few
data regarding long-term follow-up are available. Bertaglia
et al. reported a cumulative probability of AF of 63% at 4
years in their series with a mean follow-up of 20.5± 12.4
months [9]. Of note, their study protocol included routine
Holter recordings at 1, 3 and 6months thereafter, which may
have documented episodes of AF in otherwise asymptomatic
patients. Gilligan et al. reported a 33% rate of freedom from
AF or atypical AFL at 5 years, with a mean follow-up of
17± 7 months [15]. In our study, which included fairly sim-
ilar patients in terms of age, left ventricular function and
LA diameter, nearly three out of four patients experienced
postablation AF after an extended follow-up. After an ini-
tial phase consisting of the ﬁrst 2 years after the ablation,
during which most of the episodes occurred, AF preva-
lence increased continuously without seeming to reach a
plateau.
In any case, it should be noted that in our study, as in
others, a substantial number of patients received AADs and
anticoagulants ‘‘in the long term’’, highlighting the impor-
tance of the arrhythmic burden independent of the relapse
of AFL [8].
Even in the subset of patients with lone AFL, postablation
AF is a major concern. During 6—23months of follow-
up, 7—43% of such patients develop AF [6,8,12,17,18,21].
Recently, Chinitz et al. [11] reported a 50% incidence of
postablation AF in patients followed for 29.6± 21.7 months
and Ellis et al. [14] reported an even higher rate of 82% after
a follow-up of 39± 11 months. In the latter study, patients
have been treated unsuccessfully with at least two or more
AADs to enter the study. Patients in their study might have
been at higher arrhythmic risk than ours. Indeed, no restric-
tions were applied in our study, in which RF ablation was
ﬁrst-line therapy in 10 (14%) patients with lone AFL and
second-line therapy after only one failed AAD in 34 (48%)
patients.
Predictors of postablation AF
Studies with midterm follow-up have demonstrated that a
history of preablation AF [6,9,12,13,15,16,19], LA enlarge-
ment [8,9] and left ventricular dysfunction [12,19] are
related to the occurrence of AF after AFL ablation. Our
study conﬁrms the importance of the ﬁrst two factors as
predictors of postablation AF, but left ventricular dysfunc-
tion is no longer a risk factor for postablation AF in the
long term. In the subset of patients with lone AFL, mitral
regurgitation [12], LA size [14] and the number of previ-
ously used AADs [8] have been correlated with postablation
AF in the literature. No predictors of subsequent AF were
identiﬁed in this subset of patients in our study, proba-
bly because of an insufﬁcient number of patients with lone
AFL.531
tudy limitations
ecurrence of atrial arrhythmias was investigated by means
f serial ECGs and Holter recordings if patients presented
uggestive symptoms. Lack of routine monitoring may have
issed asymptomatic and paroxysmal episodes of AFL and
F, which may account for a third to more than a half of total
pisodes of arrhythmias [9,32]. Consequently, the incidence
f AF might have been underestimated. Furthermore, 29%
f patients were maintained on AADs at hospital discharge
nd 35% were using AADs at the end of follow-up. Thus, in a
ertain number of patients the results should be interpreted
s the consequence of the combination of RF ablation and
AD therapy rather than RF ablation alone.
In some cases, patients can experience clinical improve-
ent despite a few relapses of AF [7,10]. In our series,
8 patients with postablation AF had a unique and self-
erminating episode. Caution should be advised in the
nterpretation of the incidence of AF as it may not always
eﬂect the clinical status of an individual patient.
onclusions
espite the efﬁcacy of cavotricuspid isthmus RF ablation
n the treatment of typical AFL, most patients cannot be
onsidered deﬁnitely cured of all atrial tachyarrhythmias.
ndeed, three out of four patients will potentially experi-
nce AF over time. Patients with a history of preablation
F or LA enlargement are at a higher risk of postablation
F and should be monitored closely. Clinicians should be
ware of the risk of AF after the procedure, even after
he ﬁrst 2 years. Consequently, improvement of symptoms
ather than complete freedom from arrhythmias should be
f paramount importance when deciding whether to refer
atients for ablation.
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